Close Menu

Sysmex

Sysmex anticipates delivering the kit to Japanese medical institutions this month for diagnosis of the SARS-CoV-2 infection.

Contributing to the Japanese diagnostic firm's higher revenues were increased instrument and reagent sales both domestically and internationally.

The partners aim to develop new diagnostic technologies and businesses, with a focus on diseases for which there are no established diagnostic methods.

Uppsala University spinout Astrego has developed a system to rapidly detect bacterial infection and antibiotic susceptibility in biofluid.

The reagent is used for the detection of cytokeratin 19 mRNA in surgically removed sentinel lymph nodes in order to diagnose lymph node metastasis.

The Nexus IB10 is a point-of-care platform that automatically separates plasma from whole blood for analyses with a range of different tests.

The test, which will be developed using the companies' respective technologies, will be marketed by Biolidics following clinical validation.

The company posted higher total sales for the first half of its fiscal year 2020 on sales growth in both in Japan and internationally.

The two companies have  been working together since February and now are formalizing plans to develop and test new products.

Pages